WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”) (OTC: ACTC.PK) reported that it is feasible to differentiate and mature human embryonic stem cells (hESCs) into functional oxygen-carrying red blood cells (RBCs) under conditions suitable for scale-up. The research, which appears online (pre-published ahead of print) in the journal Blood –the leading publication in the field --by ACTC and its collaborators at the Mayo Clinic and the University of Illinois, shows for the first time that the oxygen-carrying capacity of hESC-derived blood cells is comparable to normal transfusable RBCs, and that the cells respond to biochemical changes in a physiologically effective manner.
